Research Highlights:
Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 2, 2026
DALLAS, Nov. 2, 2026 — Contemporary hormone replacement therapy (HRT) was not associated with an increased risk for heart attack, stroke, blood clots or death among women ages 45 to 59, according to a large, long-term study of over 52,000 women in Israel. The findings from this new, independent, preliminary research will be presented at the American Heart Association’s Scientific Sessions 2026 . The meeting, Nov. 6-9, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
“Concerns that hormone replacement therapy may affect the heart is one of the most common reasons women decline hormone therapy to manage menopause symptoms, and why some healthcare professionals may hesitate to offer it,” said lead study researcher Ronen Arbel, Ph.D., a researcher in the community medical services division of Clalit Health Services in Tel Aviv, Israel, and a researcher with Sapir College’s Maximizing Health Outcomes Research Lab in Sderot, Israel.
Previous randomized trials found associations between HRT and cardiovascular harm. However, results were mixed, and much of that evidence was from studies with older HRT formulations that are no longer commonly used, with higher doses and in women who started on HRT long after menopause. Current clinical guidelines from the American College of Obstetricians and Gynecologists recommend starting HRT within 10 years of menopause onset and before age 60. In November 2025, the FDA removed the “black box” warnings from HRT products after a comprehensive review of current scientific data indicating that HRT is not associated with increased risk of cardiovascular disease, breast cancer or dementia.
“For many women, menopause symptoms can significantly affect their quality of life, yet questions about the cardiovascular safety of hormone therapy have remained,” said Stacey E. Rosen, M.D., FAHA, an expert in women’s heart health and past volunteer president of the American Heart Association (2025-2026). “This large, long-term study adds to growing evidence that today's hormone therapy options may not increase the risk of heart disease, stroke or blood clots for healthy women who begin treatment around the time of menopause. These findings can help women and their healthcare teams have more informed conversations about the benefits and risks of treatment based on their individual health needs.” Rosen, who was not involved in this study, is also executive director of the Katz Institute for Women’s Health and senior vice president of women’s health at Northwell Health in New York City.
The study to be presented at the American Heart Association’s Scientific Sessions evaluated data for over 52,000 women, ages 45 to 59, to assess whether the use of contemporary HRT is associated with an increased risk of atherosclerotic cardiovascular disease , venous thromboembolism (blood clots) or premature death (before age 80) in women who had not been previously diagnosed with cardiovascular disease.
After an average of 12 years of follow-up, the health outcomes were similar between the two groups of women, meaning the group who started taking HRT did not show an increase in cardiovascular events or early death compared to the group that was not taking HRT.
What are the study’s main findings?
“Our results indicate that, for women in their mid-forties to late fifties with no history of heart disease or blood clots, the currently available hormone therapies prescribed to manage menopause symptoms do not appear to raise the risk of heart attack, stroke, clots or early death, even after long-term use,” Arbel said.
Study details, background and design:
The research has several limitations. It is an observational study, so it cannot prove a direct connection between HRT and heart health. The researchers also noted that there may be other differences among the women taking HRT vs. those who do not that was not available or detailed in the health records, such as differences in exercise, diet, other health conditions and severity of menopause symptoms. Additionally, the study grouped women by the first type of hormone therapy they used and did not include any changes in HRT type or formulation throughout the follow-up period.
Co-authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here .
Additional Resources:
###
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org , Facebook , X or by calling 1-800-AHA-USA1.